Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, 'Eisai') announced today the company will present the latest findings on lecanemab (U.S. brand name: LEQEMBI®), Eisai's anti-amyloid beta (Aβ) protofibril* antibody for the treatment of Alzheimer's disease (AD), at the 2024 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (AD/PD™) from March 5-9 in Lisbon, Portugal, and virtually.

卫材株式会社（总部：东京，首席执行官：Haruo Naito，“卫材”）今天宣布，该公司将介绍关于lecanemab（美国品牌：LEQEMBI®）的最新发现，卫材的抗淀粉样β（Aβ）原纤维*抗体用于治疗阿尔茨海默氏病（AD），在3月5日至9日于葡萄牙里斯本举行的2024年阿尔茨海默病和帕金森病及相关神经系统疾病国际会议（AD/PD™）上。

The lecanemab data and additional research findings from Eisai's AD portfolio will be featured in 18 presentations, including ten oral presentations..

来自卫材广告组合的lecanemab数据和其他研究结果将在18场演讲中展示，其中包括10场口头演讲。

Eisai will present five oral presentations and one poster presentation on lecanemab results. From the Phase 3 Clarity AD study in subjects with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD dementia (collectively known as early AD) with confirmed brain Aβ accumulation, presentations will include data on the effect of lecanemab treatment on tau accumulation in whole brain regions, and outcomes of long-term efficacy of lecanemab.

卫材将就lecanemab结果进行五次口头演示和一次海报演示。根据由阿尔茨海默病（AD）和轻度AD痴呆（统称为早期AD）引起的轻度认知障碍（MCI）受试者的3期Clarity AD研究，证实了大脑Aβ的积累，介绍将包括关于lecanemab治疗对全脑区域tau积累的影响的数据，以及lecanemab长期疗效的结果。

In addition, the differences in the binding properties of multiple anti-amyloid (Aβ) antibodies to various types of Aβ and other data will be presented. Eisai will also host a symposium titled 'Defining meaningful benefits to patients, caregivers, and healthcare systems in Alzheimer's disease'..

此外，将介绍多种抗淀粉样蛋白（Aβ）抗体与各种类型的Aβ和其他数据的结合特性的差异。卫材还将主办一场题为“为阿尔茨海默病患者、护理人员和医疗保健系统定义有意义的益处”的研讨会。

'Lecanemab treatment of early AD in the Phase 3 Clarity AD study had less clinical decline and slower tau accumulation than placebo,' said Michael Irizarry, M.D., Deputy Chief Clinical Officer and Senior Vice President of Clinical Research at Eisai Inc. 'The earlier MCI due to AD and mild AD dementia are diagnosed and treated, the greater the opportunity for the patient to benefit.

Eisai Inc.副首席临床官兼临床研究高级副总裁迈克尔·伊里扎里（Michael Irizarry）医学博士说：“在Clarity AD 3期研究中，Lecanemab治疗早期AD的临床下降幅度较小，tau积累速度较慢。由于AD和轻度AD痴呆而导致的MCI越早被诊断和治疗，患者受益的机会就越大。

We will continue to share the importance of and rationale for early treatment with lecanemab to the scientific community.'.

我们将继续向科学界分享早期使用lecanemab治疗的重要性和理由。”

Eisai Symposium – Defining meaningful benefits to patients, caregivers, and healthcare systems in Alzheimer's disease. Eisai is sponsoring a symposium featuring three prominent clinical experts in the field of AD, Dr. Jeffrey Cummings, Dr. Robert Perneczky and Dr. Miia Kivipelto. Dr. Jeffrey Cummings will chair the symposium, and provide an overview of meaningful benefits, including clinical meaningfulness and the evolution of approaches for the clinical study of AD.

卫材研讨会-为阿尔茨海默病患者、护理人员和医疗保健系统定义有意义的益处。卫材正在主办一个研讨会，由AD领域的三位著名临床专家Jeffrey Cummings博士，Robert Perneczky博士和Miia Kivipelto博士参加。Jeffrey Cummings博士将主持研讨会，并概述有意义的益处，包括临床意义和AD临床研究方法的演变。

Dr. Robert Perneczky will discuss how to assess meaningful benefits of treatments in development for AD. Dr. Miia Kivipelto's presentation will provide new statistical methods to measure meaningful benefits and address various stakeholder perspectives. (Thursday, March 7, 11:10-12:50).

Robert Perneczky博士将讨论如何评估AD治疗在发展中的有意义的益处。Miia Kivipelto博士的演讲将提供新的统计方法来衡量有意义的益处并解决各种利益相关者的观点。（3月7日，星期四，11:10-12:50）。

Eisai's Chief Clinical Officer, Lynn Kramer, M.D., will give a plenary presentation as 'Novel approaches to clinical development and the future potential of simulated placebo' on March 7 at the 'Aβ TARGETING THERAPIES IN AD 1' session.

卫材的首席临床官Lynn Kramer医学博士将于3月7日在“AD 1中的aβ靶向疗法”会议上发表一篇题为“临床开发的新方法和模拟安慰剂的未来潜力”的全体演讲。